Search results
Showing 1 to 15 of 41 results for brachytherapy
Low dose rate brachytherapy for localised prostate cancer (IPG132)
Evidence-based recommendations on low dose rate brachytherapy for localised prostate cancer. This involves placing small radioactive seeds into the prostate that give off low doses of radiation to destroy cancer cells.
View recommendations for IPG132Show all sections
Sections for IPG132
High dose rate brachytherapy for carcinoma of the cervix (IPG160)
Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.
View recommendations for IPG160Show all sections
Sections for IPG160
Preoperative high dose rate brachytherapy for rectal cancer (IPG531)
Evidence-based recommendations on preoperative high dose rate brachytherapy for rectal cancers. This involves inserting an applicator into the rectum and using it to deliver radiation to the tumour.
Epiretinal brachytherapy for wet age-related macular degeneration (IPG415)
Evidence-based recommendations on epiretinal brachytherapy for wet age related macular degeneration. This involves using radiation therapy used to destroy the new blood vessels.
View recommendations for IPG415Show all sections
Sections for IPG415
NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised
Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.
View recommendations for IPG268Show all sections
Sections for IPG268
Evidence-based recommendations on high dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer. This involves using radiotherapy to treat the cancer from both outside of the body and from within the affected area.
View recommendations for IPG174Show all sections
Low-energy contact X-ray brachytherapy for rectal cancer (IPG809)
Evidence-based recommendations on low-energy contact X-ray brachytherapy for rectal cancer. This involves inserting an X-ray tube through the anus into the rectum. The tube is placed in contact with the tumour and releases a low dose of X-ray radiation (brachytherapy) directly to it.
View recommendations for IPG809Show all sections
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Recommendation ID IPG415/1 Question Epiretinal brachytherapy for wet age-related macular degeneration (AMD) should only be used in the
Evidence-based recommendations on using coronary artery stents in adults.
NICE encourages further research into preoperative high dose rate brachytherapy for rectal cancer. Trials should be designed to provide...
Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.
View recommendations for IPG752Show all sections
Evidence-based recommendations on laparoscopic radical prostatectomy. This involves removing the prostate gland and some surrounding tissue using specialised instruments through small cuts in the abdomen (keyhole surgery).
View recommendations for IPG193Show all sections
Sections for IPG193